Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Dopamine hypothesis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    8 result(s) found for: Dopamine hypothesis. Displaying page 1 of 1.
    EudraCT Number: 2014-002002-20 Sponsor Protocol Number: 2014METAL1 Start Date*: 2015-06-10
    Sponsor Name:UMCG
    Full Title: A multicentre randomized double-blind placebo controlled discontinuation trial of methylphenidate
    Medical condition: attention-deficit/hyperactivity disorder
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003028-35 Sponsor Protocol Number: CTU/2016/278 Start Date*: 2019-09-04
    Sponsor Name:University College London Comprehensive Clinical Trial Unit
    Full Title: A randomised, double blind, parallel group, placebo controlled, Phase 3 trial of exenatide once weekly over 2 years as a potential disease modifying treatment for Parkinson's disease.
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2010-022363-35 Sponsor Protocol Number: mnp_001 Start Date*: 2011-02-18
    Sponsor Name:Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
    Full Title: Impact of Levodopa vs. Rotigotine on stress hormones and NGF in patients with Parkinson's Disease: A randomised, placebo-controlled double-blind trial.
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    12.1 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000335-17 Sponsor Protocol Number: MPR001 Start Date*: 2014-10-28
    Sponsor Name:Research and Development University Hospital of North Staffordshire [...]
    1. Research and Development University Hospital of North Staffordshire
    2. Keele University
    Full Title: The Effect of Rotigotine on Memory in Idiopathic Parkinson's Disease without Cognitive Impairment
    Medical condition: Idiopathic Parkinson's Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001489-17 Sponsor Protocol Number: SIOPENRNET003 Start Date*: 2006-11-17
    Sponsor Name:St. Anna Kinderkrebsforschung e.V.
    Full Title: High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN)
    Medical condition: High Risk Neuroblastoma
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Completed) ES (Restarted) GB (GB - no longer in EU/EEA) BE (Completed) DK (Restarted) IT (Completed) IE (Completed) HU (Completed) FI (Completed) SI (Completed) PL (Completed) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004507-23 Sponsor Protocol Number: 3112004 Start Date*: 2016-03-15
    Sponsor Name:Orion Corporation
    Full Title: Efficacy and safety of ODM-104 compared to a standard combination (Stalevo); a randomised, double-blind, crossover proof-of-concept study in patients with Parkinson's disease and end-of-dose wearin...
    Medical condition: Parkinson's disease (PD) patients with end-of-dose wearing-off (motor fluctuations)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) DE (Completed) HU (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2017-001219-35 Sponsor Protocol Number: COR-2017-01 Start Date*: 2018-01-22
    Sponsor Name:Cortendo AB
    Full Title: A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open-label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenou...
    Medical condition: Endogenous Cushing´s syndrome (CS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004860 10011657 Cushings syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) BG (Completed) HU (Completed) PL (Completed) NL (Completed) DK (Prematurely Ended) GR (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2012-000778-46 Sponsor Protocol Number: LiBiDi-EK314/11 Start Date*: 2013-01-17
    Sponsor Name:Forschungszentrum Jülich GmbH
    Full Title: Elucidation of Lithium Working Mechanism in Bipolar Disorder by means of Multi Modal Brain Imaging (LiBiDi)
    Medical condition: Healthy volunteers Bipolar patients type 1
    Disease: Version SOC Term Classification Code Term Level
    14.1 10018065 - General disorders and administration site conditions 10043890 Tiredness LLT
    14.1 10017947 - Gastrointestinal disorders 10028821 Nausea with vomiting LLT
    14.1 10029205 - Nervous system disorders 10013575 Dizziness and giddiness LLT
    14.1 10029205 - Nervous system disorders 10051385 Drug-induced headache LLT
    14.1 10018065 - General disorders and administration site conditions 10021689 Increased thirst LLT
    14.1 10027433 - Metabolism and nutrition disorders 10036164 Poor weight gain LLT
    14.1 10029205 - Nervous system disorders 10044577 Tremor of hands LLT
    14.1 10029205 - Nervous system disorders 10027176 Memory loss LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jul 04 16:17:06 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA